![]() |
|
|
Vol. 294, Issue 1, 45-51, July 2000
Centre Hospitalier Universitaire de Québec, Centre de
recherche du Pavillon l'Hôtel-Dieu de Québec, Quebec,
Canada
The human genes corresponding to the two receptor (R) subtypes for
bradykinin (BK)-related peptides, the B1R and
B2R, are known to be polymorphic. The human isolated
umbilical vein responds by contractions to stimulation by kinins via
constitutive B2Rs and inducible B1Rs. Vascular
rings from 100 different umbilical cords were submitted to a
standardized protocol where Emax values were
obtained at 2 and 6 h of incubation, and EC50 values
were estimated at 6 h for the B1R agonist
Sar-[D-Phe8]des-Arg9-BK;
Emax and EC50 values were also
obtained for the B2R agonist BK at 4 h. The genotype
of each tissue donor was determined for two polymorphic sites in the
B1R gene and three such sites in the B2R gene. The
(
/
) genotype of a frequent insertion/deletion polymorphism of the
B2R exon 1 was associated with increased contractile
efficiency of the B1R agonist,
Sar-[D-Phe8]des-Arg9-BK, but
had no effect on BK-induced contractility. A B2R exon 2 polymorphism (C181
T) selectively influenced the
potency of BK (EC50 higher when the T
allele was present). The other polymorphisms studied were not found to
affect kinin-induced contractility. Although most of the frequent
polymorphic alleles of the kinin receptor genes are functionally
neutral or determine functional alterations that are not detectable
using the method used here, two B2R polymorphic sites (exon
1, exon 2) modestly influence function. As the exon 1 B2R
polymorphism predicts the response of the B1R agonist, it may be in linkage disequilibrium with an unknown, functionally important polymorphism of the neighboring
B1R gene.
This article has been cited by other articles:
![]() |
L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Dhamrait, J. R. Payne, P. Li, A. Jones, I. S. Toor, J. A. Cooper, E. Hawe, J. M. Palmen, P. T.E. Wootton, G. J. Miller, et al. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension Eur. Heart J., September 2, 2003; 24(18): 1672 - 1680. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maestri, A. F. Milia, M. B. Salis, G. Graiani, C. Lagrasta, M. Monica, D. Corradi, C. Emanueli, and P. Madeddu Cardiac Hypertrophy and Microvascular Deficit in Kinin B2 Receptor Knockout Mice Hypertension, May 1, 2003; 41(5): 1151 - 1155. [Abstract] [Full Text] [PDF] |
||||